Drug Price Trends for TURQOZ-28 TABLET

Average Pharmacy Cost for TURQOZ-28 TABLET

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
TURQOZ-28 TABLET	68180-0895-11	0.34661	EACH	2024-12-18
TURQOZ-28 TABLET	68180-0895-13	0.34661	EACH	2024-12-18
TURQOZ-28 TABLET	68180-0895-11	0.31912	EACH	2024-11-20
TURQOZ-28 TABLET	68180-0895-13	0.31912	EACH	2024-11-20

Market Analysis and Price Projections for Turqoz® (Norgestrel and Ethinyl Estradiol) Tablets

Introduction to Turqoz®

Turqoz® (Norgestrel and Ethinyl Estradiol) Tablets USP, 0.3 mg/0.03 mg, is a generic equivalent of Lo/Ovral-28, a contraceptive drug developed by Wyeth Pharmaceuticals LLC. Recently, Lupin Limited received approval from the U.S. FDA to market this generic version, marking a significant entry into the U.S. pharmaceutical market[1][5].

Market Demand and Competition

The contraceptive market, particularly for combined oral contraceptives like Turqoz®, is substantial and stable. The demand for these medications is driven by the need for effective birth control methods. Lo/Ovral-28, the reference listed drug (RLD), had estimated annual sales of USD 33 million in the U.S. as of October 2023, indicating a robust market for this type of medication[1].

Pricing Dynamics

The pricing of Turqoz® is expected to be competitive, given its status as a generic drug. Generic drugs typically offer significant cost savings compared to their brand-name counterparts. For instance, Low-Ogestrel-28, another generic version of Lo/Ovral-28, is priced around $64 for a supply of 168 tablets, which translates to approximately $0.38 per unit[2].

Cost Savings and Accessibility

The introduction of Turqoz® is likely to enhance accessibility to contraceptive medications due to its lower cost. Generic drugs often reduce the financial burden on patients, making essential medications more affordable. Patient assistance programs, although not currently available for Low-Ogestrel-28, might be explored by Lupin to further reduce costs for eligible patients[2].

Regulatory Environment

The approval of Turqoz® by the U.S. FDA underscores the regulatory framework's support for generic drugs. This approval process ensures that generic medications meet the same standards of safety and efficacy as their brand-name counterparts. The evolving regulatory landscape, as predicted for the biopharma and biotech industries, is likely to continue supporting the development and approval of generic drugs[3].

Manufacturing and Distribution

Lupin Limited, with its extensive global presence and manufacturing capabilities, is well-positioned to meet the demand for Turqoz®. The tablets will be manufactured at Lupin’s Pithampur facility in India, ensuring a reliable supply chain. Lupin’s global reach, including over 100 markets, will facilitate widespread distribution of the drug[1][5].

Market Projections

Given the established demand for Lo/Ovral-28 and the cost savings associated with generic drugs, Turqoz® is expected to capture a significant share of the market.

• Short-Term Projections: In the immediate future, Turqoz® is likely to see strong adoption due to its lower price point compared to the brand-name version. This could lead to a substantial market share within the first year of launch.
• Long-Term Projections: Over the long term, the market for Turqoz® is expected to remain stable, driven by the ongoing need for effective and affordable contraceptive options. The estimated annual sales of USD 33 million for Lo/Ovral-28 provide a baseline for potential sales of Turqoz®.

Impact on the Pharmaceutical Market

The launch of Turqoz® reflects broader trends in the pharmaceutical industry, including the increasing importance of generic drugs and the evolving regulatory landscape.

• Generic Drug Market Growth: The biopharma market, including generic drugs, is projected to grow significantly, with the biopharma market size estimated to be over US$400 billion by 2029, growing at a CAGR of 7.56% between 2024 and 2029[3].
• Patient-Centered Care: The shift towards patient-centered care and the use of innovative clinical trial designs are expected to further enhance the development and approval of generic drugs, benefiting patients by providing more affordable treatment options[3].

Key Takeaways

• Market Demand: Strong and stable demand for combined oral contraceptives.
• Pricing: Competitive pricing expected, offering significant cost savings.
• Regulatory Approval: Approved by the U.S. FDA, ensuring safety and efficacy.
• Manufacturing and Distribution: Reliable supply chain through Lupin’s global manufacturing and distribution network.
• Market Projections: Expected to capture a significant market share due to its lower price point and established demand.

FAQs

Q: What is Turqoz® and what is it used for? A: Turqoz® (Norgestrel and Ethinyl Estradiol) Tablets USP is a generic contraceptive drug used to prevent pregnancy.

Q: How much does Turqoz® cost? A: The cost of Turqoz® is expected to be competitive, similar to other generic versions of Lo/Ovral-28, which are priced around $64 for a supply of 168 tablets.

Q: Who manufactures Turqoz®? A: Turqoz® is manufactured by Lupin Limited at their Pithampur facility in India.

Q: What is the estimated annual sales potential for Turqoz®? A: The estimated annual sales for Lo/Ovral-28, the RLD, were USD 33 million in the U.S., providing a baseline for potential sales of Turqoz®.

Q: Are there any patient assistance programs available for Turqoz®? A: Currently, there are no patient assistance programs available for Low-Ogestrel-28, but Lupin may explore such programs in the future.

Sources

1. Lupin Launches Turqoz® (Norgestrel and Ethinyl Estradiol) Tablets USP in the United States - Lupin.
2. Low-Ogestrel-28 Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com.
3. 5 Predictions for the Biopharma and Biotech Industries in 2025 - TFS CRO.
4. Drug patent and exclusivity study - USPTO.
5. Lupin Receives Approval from US FDA for Turqoz® (Norgestrel and Ethinyl Estradiol Tablets USP) - Lupin.